Viridian Therapeutics (VRDN) 10-K 27 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 15, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	SIGNAL GENETICS, INC.
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		7,504,990
Entity Public Float			$10,900,000
Amendment Flag	FALSE
Entity Central Index Key	1590750
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS
Cash	$5,119	$209
Restricted cash	50	50
Accounts receivable, net	1,088	994
Inventory	179	357
Prepaid expenses and other current assets	349	445
Total current assets	6,785	2,055
Property and equipment, net	1,214	928
Deferred offering costs	47	655
Security deposits	43	35
Total assets	8,089	3,673
LIABILITIES AND STOCKHOLDERS’ EQUITY/MEMBERS’ DEFICIENCY
Accounts payable	255	100
Accrued liabilities	361	271
Amounts due to related party	1,045
Lease termination/abandonment payable - current portion	248	319
Capital lease liability–current portion	80
Note payable – current portion		42
Note payable – related party		26,569
Total current liabilities	1,989	27,301
Other noncurrent liabilities	109
Lease termination/abandonment payable		259
Commitments and contingencies
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2014 or 2013	0	0
Common stock, $0.01 par value, 50,000,000 shares authorized, 3,782,629 shares issued and outstanding at December 31, 2014 and no shares issued and outstanding at December 31, 2013	38
Additional paid in capital	12,593
Accumulated deficit	-6,640
Members’ deficiency		-23,887
Total stockholders’ equity (members’ deficiency)	5,991	-23,887
Total liabilities and stockholders’ equity/members’ deficiency	$8,089	$3,673

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock par value (in Dollars per share)	$0.01	$0.01
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock outstanding	0	0
Common stock par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	3,782,629	0
Common stock, shares outstanding	3,782,629	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net revenue	$4,320,000	$4,316,000
Cost of revenue	3,243,000	2,778,000
Research and development	293,000	225,000
Selling and marketing	717,000	349,000
General and administrative	7,034,000	1,411,000
Gain on legal settlement	-100,000	-250,000
Total operating expenses	11,187,000	4,513,000
Loss from operations	-6,867,000	-197,000
Interest expense	-1,023,000	-1,963,000
Net loss	-7,890,000	-2,160,000
Dividend to member unit holder of Myeloma Health LLC		-285,000
Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	-7,890,000	-2,445,000
Net loss per common share, basic and diluted (in Dollars per share)	($3.50)	($12.23)
Weighted-average number of shares outstanding, basic and diluted (in Shares)	2,255,864	200,000
Predecessor [Member]
Net loss	-1,250,000	-2,160,000
Successor [Member]
Net loss	($6,640,000)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders’ Equity and Members’ Deficiency (USD $)

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Retained Earnings [Member]

Capital Units [Member]

Capital Units [Member]

Capital Units [Member]

Members' Deficiency [Member]

Members' Deficiency [Member]

Members' Deficiency [Member]

Predecessor [Member]

Successor [Member]

Capital Unit, Class A [Member]

Capital Unit, Class B [Member]

Capital Unit, Class C [Member]

Total

In Thousands, except Share data

USD ($)

USD ($)

Successor [Member]

USD ($)

Capital Unit, Class A [Member]

Capital Unit, Class B [Member]

Capital Unit, Class C [Member]

Predecessor [Member]

Successor [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Dec. 31, 2012

[1]

($21,442)

Balance (in Shares) at Dec. 31, 2012

72,500

41,088

Balance, December 31, 2014

-23,887

Distributions

-285

[1]

-285

Net loss

-2,160

[1]

-2,160

-2,160

Balance at Dec. 31, 2013

-23,887

[1]

-23,887

Balance (in Shares) at Dec. 31, 2013

72,500

41,088

Balance, December 31, 2014

38

12,593

-6,640

[1]

5,991

Balance, December 31, 2014 (in Shares)

3,782,629

Conversion of note payable to Class C Units

[1]

27,326

Conversion of note payable to Class C Units (in Shares)

2,732,629

Net loss

-6,640

-1,250

[1]

[1]

-1,250

-6,640

-7,890

Conversion from Limited Liability Company to Corporation

29

2,160

-2,189

[1]

2,189

Conversion from Limited Liability Company to Corporation (in Shares)

2,932,629

-72,500

-41,088

-2,732,629

Initial public offering of common shares, net of costs to issue

9

5,835

[1]

5,844

Initial public offering of common shares, net of costs to issue (in Shares)

850,000

Fair value of warrants and option to underwriters for overallotment shares issued in connection with initial public stock offering

300

[1]

300

Stock-based compensation

$4,298

[1]

$4,298

Balance at Dec. 31, 2014

Balance (in Shares) at Jun. 16, 2014

72,500

41,088

Conversion from Limited Liability Company to Corporation (in Shares)

200,000

2,732,629

2,932,629

Balance at Jun. 17, 2014

[1]

Members' deficiency was reclassified to additional paid-in capital upon conversion from the Limited Liability Company to the Corporation.

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
OPERATING ACTIVITIES
Net loss	($7,890,000)	($2,160,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	4,298,000
Depreciation and amortization	144,000	148,000
Bad debt expense	177,000
Noncash interest on note payable – related party	1,007,000	1,937,000
Lease termination	46,000
Gain on legal settlement	-100,000	-250,000
Changes in operating assets and liabilities:
Accounts receivable	-271,000	202,000
Inventory	178,000	-187,000
Prepaid expenses and other current assets	191,000	-65,000
Accounts payable and accrued liabilities	383,000	-280,000
Lease termination/abandonment payable	-376,000	-319,000
Net cash used in operating activities of discontinued operations		-194,000
Net cash used in operating activities	-2,213,000	-1,168,000
INVESTING ACTIVITIES
Purchases of property and equipment	-266,000	-5,000
(Increase) decrease in security deposits	-8,000	11,000
Net cash provided by (used in) investing activities	-274,000	6,000
FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of costs to issue	6,644,000	-500,000
Proceeds from issuance of note payable/amounts due to related party	795,000	12,566,000
Repayment of note payable – related party		-10,461,000
Repayment of note payable	-42,000	-61,000
Distributions to member		-285,000
Net cash provided by financing activities	7,397,000	1,259,000
Net increase in cash	4,910,000	97,000
Cash, beginning of period	209,000	112,000
Cash, end of period	5,119,000	209,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	1,000	1,209,000
Noncash investing and financing activities:
Conversion of note payable to Class C Units	27,326,000
Asset acquired under capital lease	$164,000

Note_1_Basis_of_Presentation

Note 1 - Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1.	Basis of Presentation
	Signal Genetics, Inc. (the “Company,”) was originally formed as Myeloma Health LLC, in January 2010. Effective January 1, 2011 with the formation of Signal Genetics LLC, substantially all the members’ interests in Myeloma Health LLC were exchanged for members’ interests in Signal Genetics LLC and Myeloma Health LLC became a subsidiary of the Company.
	Corporate Conversion and Initial Public Offering
	On June 17, 2014, the Company completed a corporate conversion and Signal Genetics LLC converted from a limited liability company to a Delaware corporation (the “Corporate Conversion”). Immediately prior to the Corporate Conversion, $27.3 million of the Company’s note payable — related party was converted into 2,732,629 newly authorized Class C units (the “Debt Conversion”). In connection with the Corporate Conversion, all outstanding Class A and C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for an aggregate of 2,932,629 shares of common stock of the Company, the members of Signal Genetics LLC became stockholders of the Company and the Company succeeded to the business of Signal Genetics LLC and its consolidated subsidiaries.
	On June 23, 2014, the Company completed an initial public offering (the "IPO") of 850,000 shares of its common stock, at $10.00 per share, for net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash fair values of warrants and option for overallotment shares issued in connection with the IPO.
	Basis of Presentation and Liquidity
	The accompanying consolidated financial statements include the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
	The Company is a commercial stage, molecular genetic diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. In 2010, the Company became the exclusive licensee to the intellectual property stemming from the renowned research on multiple myeloma (“MM”), performed at the University of Arkansas for Medical Sciences (“UAMS”). Myeloma Prognostic Risk Signature (“MyPRS®”) is based upon 30 years of clinical research on nearly 10,000 MM patients who received their care at UAMS. The Company currently generates revenues from the performance of MyPRS® diagnostic tests, which was launched in April 2011.
	Since its inception, the Company has devoted substantial effort in developing its products and services and has incurred losses and negative cash flows from operations. Prior to its IPO, all financial support had been provided by the majority member. As of December 31, 2014, however, following the Debt Conversion, the Corporate Conversion and the IPO, the Company has positive working capital and stockholders’ equity. Although the Company is forecasting continued losses and negative cash flows as it funds its expanding selling and marketing activities, and research and development programs, the Company believes that it has enough cash on hand to support operations for at least the next 12 to 15 months. Going forward, as the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note_2_Significant_Accounting_

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.	Significant Accounting Policies
	Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
	Cash
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash is currently comprised only of cash on hand and deposits in banks. At December 31, 2014 and 2013, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease.
	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded net of an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience since its inception for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered.
	During the year ended December 31, 2014, the Company discovered that $78,000 of insurance reimbursements were sent directly to patients, in error, and identified $99,000 of older Medicare and contracted insurance claims that were past the due date requirements. When the amounts were determined to be uncollectible, they were expensed as bad debt and subsequently charged off against the allowance.  Therefore, there were no allowances for doubtful accounts recorded as of December 31, 2014 or 2013.
	Inventory
	Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method.
	Property and Equipment
	Property and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in operations.
	Long Lived Assets
	Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years ended December 31, 2014 or 2013.
	Deferred Offering Costs
	During the years ended December 31, 2014 and 2013, the Company incurred $47,000 and $655,000, respectively, in direct costs related to its anticipated public offerings of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and 2013 and reclassified as a reduction to additional paid-in capital upon completion of the respective offerings in 2015 and 2014, respectively.
	Deferred Rent
	Where rent abatements are made available to the Company under the terms of a lease agreement, the abatements are accounted for as a reduction of rent expense over the life of the lease and rent expense is recognized on a straight-line basis over the entire term of the lease. The cumulative difference between actual rent payments and recognized rental expense is recorded as deferred rent in the consolidated balance sheets.
	Revenue Recognition
	Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis when the contractual obligations are completed as assays are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date.
	The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and adjusts expected revenues for current and subsequent periods accordingly. During the year ended December 31, 2014, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000 and $274,000 related to revenues previously recorded during 2012 and 2013, respectively. During the year ended December 31, 2013, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $57,000.
	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
			Years Ended December 31,
	(in thousands)		2014			2013
	Gross revenues		$	6,484		$	5,491
	Less: contractual allowance			(2,164	)		(1,175	)
	Net revenue		$	4,320		$	4,316
	Contractual allowances recorded during the years ended December 31, 2014 and 2013 represented 33% and 21% of gross revenues, respectively. The increase in contractual allowances is primarily due to net unfavorable changes in estimates of $541,000 recorded during the year ended December 31, 2014 related to current and prior years’ revenue.
	Cost of Revenue
	Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result, depreciation, amortization and royalty expense. Costs associated with performing tests are recorded as the tests are processed.
	Royalties
	The Company licenses technology for patents for uses of a gene expression profiling (“GEP”) assay called MyPRS® and its related technology. Under the terms of the license agreement, the Company is required to pay royalties to UAMS. The royalties are calculated as a fixed percentage of the net revenue received from third parties that the Company generates from using this technology. The Company accrues for such royalties when incurred, which is based on when revenue is collected. Such royalties are included in cost of revenue in the accompanying consolidated statements of operations.
	Research and Development
	Costs associated with research and development activities are expensed as incurred. Research and development costs primarily include personnel costs, laboratory supplies, reagents and consulting costs. To date, the Company has not included an allocation of any indirect costs in research and development.
	Income Taxes
	Prior to the Corporate Conversion, the Company was a limited liability company, which is not a tax paying entity at the corporate level. Each member was instead individually responsible for such member’s share of the Company’s income or loss for income tax reporting purposes. Net operating losses incurred by the Company through the date of the Corporate Conversion have been, or will be, used by the members to offset gains on other interests and are, therefore, not able to be carried forward to the Company.
	Effective as of the Corporate Conversion, deferred tax assets and liabilities are recorded for the expected future tax consequences of events that have been included in the consolidated financial statements or income tax returns. Deferred taxes are determined on the basis of the differences between the carrying amount of assets and liabilities for financial statement and income tax purposes at enacted rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.
	Applicable accounting guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Accounting provisions also require that a change in judgment that results in subsequent recognition, derecognition, or change in a measurement of a tax position taken in a prior annual period (including any related interest and penalties) be recognized as a discrete item in the period in which the change occurs. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available.
	Any interest and penalties related to unrecognized tax benefits are classified as a component of income tax expense.
	Stock-Based Compensation
	Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees is estimated at the date of grant, while the fair value of stock options granted to non-employees is estimated at the date of grant using the BSM pricing model and remeasured at each subsequent reporting date to fair value until performance is complete, with changes in fair value recognized as expense in the statement of operations and comprehensive loss.
	The fair value of restricted stock units issued to employees is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense.
	Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash, restricted cash, accounts receivable, accounts payable, amounts due to related party and notes payable.
	The carrying amounts of financial instruments such as accounts receivable and accounts payable approximate their relative fair values due to the short-term maturities of these instruments.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.
	Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.
	At December 31, 2014 and 2013, the fair value of the Company’s remaining lease liability on its vacated facility was measured using estimated net cash flows, discounted using a nominal risk-free rate, which are considered Level 3 inputs. The present value of the remaining lease liability at December 31, 2014 and 2013 was $248,000 and $578,000, respectively.
	Net Loss Per Share
	Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting.
	For all periods presented, the number of shares outstanding has been adjusted to reflect the Corporate Conversion completed on June 17, 2014 as if it had occurred as of the beginning of the respective periods presented.
	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
			December 31,
			2014
	Unvested restricted stock units			655,200
	Options to purchase common stock			152,000
	Warrants to purchase common stock			42,500
	Total			849,700
	Concentration of Credit Risk, Major Customers and Suppliers
Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances.
During the years ended December 31, 2014 and 2013, the Company had one major customer, UAMS. Revenue sourced either from or through UAMS accounted for 84% and 83% of net revenue during the years ended December 31, 2014 and 2013, respectively. Accounts receivable sourced either from or through UAMS at December 31, 2014 and 2013 accounted for 63% and 62% of total accounts receivable outstanding, respectively.
Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business.
Reclassifications
Reclassifications of certain current liabilities in the consolidated balance sheet and operating expenses in the consolidated statement of operations have been made as of and during the year ended December 31, 2013 to conform to the 2014 presentation.
Recent Accounting Pronouncements
In February 2015, the Financial Accounting Standards Board ("FASB") issued amendments to Accounting Standards Update (“ASU”) 2015-02, Consolidation: Amendments to the Consolidation Analysis. This standard simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for variable interest entities. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
In January 2015, the FASB issued ASU 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Under this standard, an entity will no longer be allowed to separately disclose extraordinary items, net of tax, in the income statement after income from continuing operations if an event or transaction is unusual in nature and occurs infrequently. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for the Company’s annual reporting period beginning January 1, 2017, including interim periods within that reporting period; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period beginning January 1, 2017, and for any annual and interim periods thereafter. Early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
Future Accounting Pronouncements
Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company, such as the Company, may take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although, to date, the Company has not taken advantage of this delay, the Company has elected to avail itself of the extended transition period for adopting new or revised accounting standards in the future. As a result of this election, the Company’s consolidated financial statements may not be comparable to companies that comply with public company effective dates.

Note_3_Balance_Sheet_Accounts_

Note 3 - Balance Sheet Accounts and Supplemental Disclosures	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	3.	Balance Sheet Accounts and Supplemental Disclosures
	Property and Equipment
	Property and equipment consist of the following:
			December 31,
	(in thousands)		2014			2013
	Laboratory and computer equipment		$	1,711		$	1,320
	Furniture and fixtures			52			13
	Leasehold improvements			6			6
				1,769			1,339
	Less: accumulated depreciation and amortization			(555	)		(411	)
	Total property and equipment, net		$	1,214		$	928
	An asset with a cost of $300,000 recorded under a capital lease is included in the laboratory equipment balance at December 31, 2014.
	Accrued Expenses
	Accrued expenses consist of the following:
			December 31,
	(in thousands)		2014			2013
	Accrued compensation and related expenses		$	257		$	76
	Accrued offering costs			42			155
	Other			62			40
	Total accrued expenses		$	361		$	271

Note_4_Notes_Payable_and_Capit

Note 4 - Notes Payable and Capital Lease Obligations	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Debt and Capital Leases Disclosures [Text Block]	4.	Amount Due Related Party, Notes Payable and Capital Lease Obligations
	Note Payable — Related Party and Amounts Due to Related Party
	During the years ended December 31, 2014 and 2013, the Company’s then majority member, through various entities controlled by such member, loaned net amounts of $795,000 and $2.1 million, respectively, to the Company to support its operations. Pursuant to the terms of an Exchange Agreement, and prior to the Corporate Conversion, $27.3 million of the Secured Note payable as of June 17, 2014 was exchanged for 2,732,629 Class C units of Signal Genetics LLC and recorded to members’ equity. The remaining $1.0 million as of that date, along with an additional $45,000, which was advanced to pay for certain offering expenses, was reclassified as unsecured amounts due to related party in the consolidate balance sheet. The aggregate amount is non-interest bearing and is due on demand.
	Subsequent to December 31, 2014, on March 6, 2015, the amounts due to related party were converted into an unsecured note payable – related party bearing interest at 8% per annum and due on demand on or after June 30, 2015. The principal amount of the note, $1.1 million, has been increased over the amounts due to related party in exchange for a provision that the related party would not call the note prior to June 30, 2015.
	Prior to the Debt Conversion, the Secured Note bore interest at 8% compounded quarterly, was due on demand and collateralized by substantially all assets of the Company. The average amount of borrowings during the years ended December 31, 2014 (prior to conversion) and 2013, were $27.4 million and $24.5 million, respectively. Interest expense related to the note for the years ended December 31, 2014 and 2013 was $1.1 million and $1.9 million, respectively. Interest was accrued and included in the note payable — related party balance reported in consolidated balance sheet at December 31, 2013. During the year ended December 31, 2013, the majority member loaned the Company $10.5 million, which was used to repay principal of $9.3 million and interest of $1.2 million owed to certain entities controlled by such member who had loaned monies to the Company under the note.
	Note Payable
	The Company acquired certain property and equipment through the issuance of a note payable for $182,000. The note was payable in thirty-six monthly installments of $5,320 and the final payment was made in October 2014. The present value of the note payable at December 31, 2013 was $42,000. The effective interest rate of the note during 2014 and 2013 was 3.4%.
	Capital Lease Obligation
	In December 2014, the Company entered into a new two-year capital lease obligation for laboratory equipment which expires in January 2017, and provides for monthly rent of $7,200. The lease also required a deposit of $136,000 which was paid in December 2014.  The lease obligation at December 31, 2014 aggregated $164,000, which is net of $8,000 in unamortized discounts. Future maturities of this obligation at December 31, 2014 are $86,000 in each of 2015 and 2016.

Note_5_Stockholders_EquityMemb

Note 5 - Stockholders’ Equity/Members’ Interests	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	5.	Stockholders’ Equity/Members’ Interests
	Preferred Shares
	The Company has authorized 5,000,000 shares of preferred stock, of which no shares were issued or outstanding at December 31, 2014. The Company’s board of directors has the authority to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences and the number of shares constituting any class or series, without further vote or action by the stockholders.
	Common Shares
	The Company has authorized 50,000,000 shares of common stock, of which 3,782,629 shares were issued and outstanding at December 31, 2014. Common shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December 31, 2014 is as follows:
	Issued and Outstanding:
	Restricted stock units			940,093
	Stock options			152,000
	Warrants			42,500
	Shares reserved for future award grants			153,306
	Total			1,287,899
	Corporate Conversion
	Immediately prior to the Corporate Conversion, Signal Genetics LLC had issued and outstanding 72,500 Class A units and 41,088 Class B units (23,328 of which were unvested). In connection with the Debt Conversion, on June 17, 2014, the note payable — related party was exchanged for 2,732,629 Class C units of the Company. On June 17, 2014, the outstanding Class A and Class C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for an aggregate of 2,932,629 shares of common stock at $10.00 per share. All outstanding Class B units, which consisted of equity incentive units, were cancelled.
	Initial Public Offering
	On June 23, 2014, the Company completed an IPO of 850,000 shares of its common stock, at $10.00 per share, for total net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash fair values of warrants and option for overallotment shares issued in connection with the IPO.
	Warrants and Option for Common Stock
	In connection with the IPO in June 2014, the Company issued warrants to certain designees of the underwriter to purchase an aggregate of 42,500 shares of common stock with an aggregate grant date fair value of $143,000. The warrants are exercisable at any time from June 17, 2015 through June 17, 2019. Also, in connection with the IPO, the Company granted a 45-day option to the underwriter to purchase up to 127,500 shares of common stock to cover overallotments, with an aggregate grant date fair value of $157,000. The aggregate fair values of the warrants and stock option issued were recorded as an increase to additional paid-in capital with an offset to the proceeds from the IPO.
	The estimated fair values of the warrants and stock option award were determined on their respective measurement dates using the BSM option valuation model with the following assumptions:
			Warrants			Options
	Fair value of common stock		$	7.84		$	10
	Exercise price		$	12.5		$	9.3
	Risk-free interest rate			1.72	%		0.035	%
	Volatility			64.6	%		63	%
	Dividend Yield			0	%		0	%
	Contractual term (in years)			5			0.12
	Weighted-average measurement date fair value per share		$	3.38		$	1.23
	Distributions to Former Member
	Distributions of $285,000 were made during the year ended December 31, 2013 to a member of Myeloma Health LLC, a subsidiary of the Company. These distributions were made in the form of dividends by the Company to Myeloma Health LLC and thereafter to the member.

Note_6_Stock_Compensation_Plan

Note 6 - Stock Compensation Plan	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6.	Stock Compensation Plan
	Effective with the IPO, the Company adopted the 2014 Stock Incentive Plan (the “Plan”) to promote long-term growth and profitability by (i) providing key people with incentives to improve stockholder value and to contribute to the Company’s growth and financial success through their future services and (ii) enabling the Company to attract, retain and reward the best-available personnel. Awards may be made in the form of incentive or non-statutory stock options, stock appreciation rights, restricted or unrestricted stock awards, restricted stock units, performance awards, or other stock-based awards. No awards may be granted after June 16, 2024. At December 31, 2014, awards for up to 1,245,399 shares of common stock may be issued under the Plan, of which 1,092,093 shares are reserved for issuance upon exercise of granted and outstanding options and vesting of restricted stock units, and 153,306 shares are available for future grants.
	Restricted Stock Units (“RSUs”)
	In connection with the IPO and through December 31, 2014, awards for RSUs were issued for an aggregate of 940,093 shares of common stock.
	All of the RSUs provide for settlement of the vested RSUs on an annual or semi-annual issuance date through (i) the delivery of shares of the Company’s common stock equal to the number of vested RSUs, (ii) payment of an amount in cash equal to the product of the fair market value of the common stock on the respective payment date and the number of RSUs vesting, or (iii) some combination of common shares and cash as referenced in (i) and (ii), respectively; all as determined by the plan administrator as of each payment date. The Company currently intends to settle all awards with shares of common stock, except for cash that may be paid to the award holder in exchange for a portion of the shares to satisfy tax withholding requirements, which shall not exceed the award holder’s minimum statutory tax withholding obligation.
	RSUs generally vest over a period of one to four years, subject to earlier cancellation or forfeiture prior to vesting upon cessation of service to the Company. The following table summarizes activity related to RSUs during the year ended December 31, 2014:
			Number of			Weighted-
			Shares			Average Grant
						Date Fair Value
						per Share
	Granted during the year ended December 31, 2014			940,093		$	9.44
	Vested and unissued			(284,893	)	$	10
	Unvested at December 31,2014			655,200		$	9.2
	The total fair value of RSUs that vested during the year ended December 31, 2014 was $2.9 million.
	Stock Options
	Stock options generally vest over a four-year period and have a maximum term of ten years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to the Company. A summary of the activity related to stock option awards during the year ended December 31, 2014 is as follows:
			Shares Subject			Weighted-		Weighted-		Aggregate
			to Options			Average		Average		Intrinsic Value
						Exercise Price		Remaining		(in thousands)
						per Share		Contractual
								Term
								(in years)
	Granted			154,500		$	4.55
	Forfeitures and cancellations			(2,500	)	$	5.43
	Outstanding at December 31, 2014			152,000		$	4.53		3.7	$	—
	Options exercisable at December 31, 2014			—		$	—		—	$	—
	Options vested or expected to vest at December 31, 2014			152,000		$	4.53		3.7	$	—
	Stock-Based Compensation Expense
	Compensation expense for time-based RSUs is measured using the fair value of the Company’s common stock on the date of grant and recognized ratably over the vesting period.
	The estimated fair value of each stock option award was determined on the date of grant using the BSM option valuation model with the following assumptions for the option grants during the year ended December 31, 2014:
	Risk-free interest rate	1.73%	-	2.03%
	Expected volatility	65.30%	-	66.90%
	Weighted-average volatility		66.30%
	Dividend yield		0%
	Expected term (in years)		6.3
	Weighted-average grant date fair value per share		$2.81
	The fair value of each stock option is estimated on the date of grant using the BSM option pricing model which requires the input of highly subjective assumptions. Because the option-pricing model is sensitive to change in the input assumptions, different determinations of the required inputs may result in different fair value estimates of the options. The risk-free interest rate is based on the rate currently available on U.S. Treasury issues with terms approximating the expected term of the option. Due to the Company’s limited historical stock data, the estimated future stock price volatility is based upon the average historical volatilities of a group of peer companies. The Company has not paid any dividends on common stock since the Corporate Conversion and does not anticipate paying dividends on common stock in the foreseeable future. The Company did not issue options prior to the IPO and, therefore, has no history of option exercises. As such, the ‘simplified’ method has been used to estimate the expected term of options.
	Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Due to the Company’s limited historical stock option forfeiture data, a forfeiture rate was not applied during the year ended December 31, 2014.
	Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations during the year ended December 31, 2014 is as follows:
	(in thousands)
	Cost of revenue		$	257
	Research and development			121
	Selling and marketing			16
	General and administrative			3,904
	Total		$	4,298
	At December 31, 2014, there was $4.3 million of unamortized compensation cost related to unvested RSUs which is expected to be recognized over a remaining weighted-average vesting period of 1.9 years. At December 31, 2014, there was $392,000 of unamortized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 3.7 years.

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	7.	Commitments and Contingencies
	Operating Leases
	The Company leases a laboratory and office facility under a non-cancellable operating lease agreement, which expires in March 2016. Monthly rent expense is $6,400.
	During 2014, the Company entered into a new lease for office space for its corporate headquarters in California, which expires in October 2017. The lease provides for monthly rent of $14,000, which will increase at a rate of 3% annually, and includes three months of rent abatement during the first year with an option to renew the lease for one additional 36-month period.
	Rent expense during the years ended December 31, 2014 and 2013 was $149,000 and $76,000, respectively. In addition, certain administrative functions were performed at an office location leased by the majority stockholder through September of 2014 at no charge to the Company. No amount has been charged for these functions as it is not deemed reasonable to estimate.
	At December 31, 2014, the future minimum annual obligations under non-cancellable operating lease commitments, excluding the abandoned lease liability described below, are $216,000, $192,000 and $148,000 during 2015, 2016 and 2017, respectively.
	Lease Abandonment
	During the 2012, the Company abandoned one of its operating leases and its attempts to sublease the related property were unsuccessful. At December 31, 2013, the present value of the remaining payments due under the lease and reported in the consolidated balance sheet is $578,000.
	In March 2014, the Company entered into a termination agreement with the landlord and agreed to a termination fee of $565,000, payable in monthly installments of $31,400 through August 2015. The present value of the remaining payments under the termination agreement at December 31, 2014 and reported in the consolidated balance sheet is $248,000. The termination agreement resulted in a change in estimate which is reported as an additional expense of $46,000 during the year ended December 31, 2014 and is included in general and administrative expenses on the consolidated statement of operations.
	Licensing Agreement
	The Company has a licensing agreement with UAMS for the exclusive use of patents used in the GEP assay, MyPRS® and its related technology through April 2020. The agreement is effective through the earlier of the expiration of the related patents or termination of the agreement pursuant to its terms. The Company may terminate the agreement for any reason upon 90 days written notice. UAMS may terminate the agreement with 90 days written notice upon a material breach of the agreement by the Company or if the Company challenges the validity of any licensed patent in a court of competent jurisdiction. Under the terms of the license agreement, the Company is required to pay $30,000 in annual minimum royalties on sales to customers other than UAMS unless sales, as defined in the agreement, exceed certain thresholds in which case the additional royalties would range from 2% – 4%. Total royalty expense during each of the years ended December 31, 2014 and 2013 was $30,000.
	Services Agreement
	The Company has a services agreement with a third party to assist with billing and collections from customers which has been automatically renewed until February 2016. The agreement contains automatic one-year renewals, unless a 90-day termination notice is given by either party. Under the terms of the agreement, fees to the third party are based on a percentage of cash collections. The Company has a minimum commitment of $10,000 per month. During the years ended December 31, 2014 and 2013, the Company paid $142,000 and $143,000, respectively, to this vendor. At December 31, 2014, the future minimum commitments under this agreement are $120,000 and $20,000 during the years ended December 31, 2015 and 2016, respectively.
	Letters of Credit
	At December 31, 2014, the Company was contingently liable for a standby letter of credit issued by a commercial bank for $50,000, for security on a lease. The Company has $50,000 in a restricted cash account that is held as cash collateral for this letter of credit.
	Litigation
	The Company is, from time to time, involved in legal proceedings, regulatory actions, claims and litigation arising in the ordinary course of business. Currently, the Company is not a defendant in any lawsuit.
	Litigation Settlement
	In August 2013, the Company settled a lawsuit in which it was the plaintiff for a tortuous interference claim regarding a potential acquisition for a payment of at least $350,000, of which $250,000 was received in January 2014 and the remaining $100,000 was received in January 2015. In addition, if the defendants have made sales of their technology by the end of 2015, the Company will also be paid the lesser of 10% of the total sales as of the end of 2015 or $100,000, with the payment to the Company due January 2016. At December 31, 2014 and 2013, the Company recorded receivables for $100,000 and $250,000, respectively, in prepaid expenses and other current assets in the consolidated balance sheets, and recognized the related gains for $100,000 and $250,000 during the years ended December 31, 2014 and 2013, respectively. The Company has not recorded the remaining future payment as either a receivable or gain as of December 31, 2014 due to the uncertainty surrounding the gain contingency. The remaining gain will be recorded when and if the cash is collected.

Note_8_Income_Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	8.	Income Taxes
	The principal items accounting for the difference in income taxes computed at the federal statutory tax rate of 34% and the effective income tax rate for the Company’s operations subsequent to the Corporate Conversion in June 2014 through December 31, 2014 are as follows:
	(in thousands)
	Federal tax at statutory rate		$	(2,682	)
	Signal Genetics LLC loss, prior to Corporate Conversion, not taxed at corporate level			425
	State taxes, net of federal benefit			(141	)
	Change in valuation allowance			1,356
	Nondeductible compensation			1,046
	Credits and other			(4	)
	Total provision for income taxes		$	—
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2014 are as follows:
	(in thousands)
	Deferred Tax Assets:
	Net operating loss carryforwards		$	853
	Stock compensation			463
	Accrued compensation			74
	Credit carryforward			6
	Total deferred tax assets			1,396
	Valuation allowance			(1,196	)
	Deferred tax assets, net of valuation allowance			200
	Deferred tax liabilities:
	Depreciation and amortization			(200	)
	Net deferred tax assets		$	—
	A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved.  Based on the available evidence at December 31, 2014, the Company was not able to conclude that it is more likely than not certain deferred tax assets will be realized.  Therefore, the Company recorded a valuation allowance of $1.2 million against deferred assets.
	As of December 31, 2014, the Company had operating loss carryforwards for federal and state tax purposes of $2.3 million and $2.2 million, which will begin to expire in 2035.  In addition, the Company has $6,000 in federal tax credits that will begin to expire in 2035.
	Internal Revenue Code Sections 382 and 383 limit the availability of income tax net operating losses and tax credit carryforwards that arise prior to certain cumulative changes in a corporation's ownership resulting in change of control of the Company should such changes in ownership occur. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within a three-year period.  The Company has not conducted a formal analysis to determine if such an ownership change has occurred.
	The Company’s 2014 tax year remains open to examination by one or more major taxing jurisdictions to which the Company is subject.

Note_9_Revision_of_Quarterly_L

Note 9 - Revision of Quarterly Losses Per Share	12 Months Ended
	Dec. 31, 2014
Accounting Changes and Error Corrections [Abstract]
Accounting Changes and Error Corrections [Text Block]	9.	Revision of Quarterly Losses Per Share
	In finalizing its annual 2014 results, the Company determined that it inadvertently included shares of common stock from its Debt Conversion in its retroactive adjustment to weighted average shares outstanding used for the determination of basic and diluted net loss per share for periods prior to its Corporate Conversion resulting in an overstatement of weighted average shares outstanding, basic and diluted, and an understatement of net loss per common share, basic and diluted. In addition, subsequent to the Corporate Conversion, the Company excluded vested restricted stock units from its determination of weighted average shares outstanding for basic and diluted net loss per share resulting in an understatement of weighted average shares outstanding, basic and diluted, and an overstatement of net loss per common share, basic and diluted.
	The Company assessed the effect of the above misstatements, individually and in the aggregate, and based on an analysis of quantitative and qualitative factors, the Company determined that the misstatements were not material to any of the Company’s prior interim financial statements and, therefore, the previously-issued financial statements could continue to be relied upon. While the errors are material on a quantitative basis, the Company reached the conclusion that, qualitatively, the errors were not material through its consideration of the following factors: 1) the Company’s current operating loss position, and current and prior financial statement disclosures that it will continue to be in a loss positon for the foreseeable future and will need to raise additional funds in order to support the Company’s anticipated increases in operating expenses, and 2) the Company believes that investors in the diagnostic testing segment of the healthcare industry are more concerned with revenue and projected revenue trends than on gross margin, net loss or income, or net loss or income per share amounts. Previously filed Quarterly Reports on Form 10-Q for quarterly periods ending prior to December 31, 2014 have not been and will not be amended.
	This Annual Report on Form 10-K restates the Company’s weighted-average number of shares outstanding, basic and diluted, and net loss per common share, basic and diluted, for its Quarterly Reports on Form 10-Q filed during 2014.
	The impact of the adjustments from the restatement is set forth below. The restatement had no effect on the consolidated balance sheets, stockholders’ equity or operating, investing or financing cash flows.
	2014
	(in thousands, except share and per share data)		For the Quarter Ended September 30, 2014									For the Nine Months Ended September 30, 2014
			As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC		$	(1,637	)	$	—		$	(1,637	)	$	(5,632	)	$	—		$	(5,632	)
	Net loss per common share, basic and diluted		$	(0.43	)	$	0.03		$	(0.40	)	$	(1.78	)	$	(1.63	)	$	(3.41	)
	Weighted-average number of shares outstanding, basic and diluted			3,782,629			279,858			4,062,487			3,162,639			(1,509,992	)		1,652,647
			For the Quarter Ended June 30, 2014									For the Six Months Ended June 30, 2014
			As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC		$	(3,289	)	$	—		$	(3,289	)	$	(3,995	)	$	—		$	(3,995	)
	Net loss per common share, basic and diluted		$	(1.13	)	$	(3.60	)	$	(4.73	)	$	(1.40	)	$	(7.52	)	$	(8.92	)
	Weighted-average number of shares outstanding, basic and diluted			2,903,040			(2,207,586	)		695,454			2,847,505			(2,399,778	)		447,727
	2013
	(in thousands, except share and per share data)		For the Quarter Ended September 30, 2013									For the Nine Months Ended September 30, 2013
			As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC		$	(940	)	$	—		$	(940	)	$	(2,196	)	$	—		$	(2,196	)
	Net loss per common share, basic and diluted		$	(0.35	)	$	(4.35	)	$	(4.70	)	$	(0.85	)	$	(10.13	)	$	(10.98	)
	Weighted-average number of shares outstanding, basic and diluted			2,672,349			(2,472,349	)		200,000			2,587,475			(2,387,475	)		200,000
			For the Quarter Ended June 30, 2013									For the Six Months Ended June 30, 2013
			As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC		$	(630	)	$	—		$	(630	)	$	(1,257	)	$	—		$	(1,257	)
	Net loss per common share, basic and diluted		$	(0.24	)	$	(2.91	)	$	(3.15	)	$	(0.49	)	$	(5.80	)	$	(6.29	)
	Weighted-average number of shares outstanding, basic and diluted			2,591,223			(2,391,223	)		200,000			2,545,013			(2,345,013	)		200,000

Note_10_Subsequent_Events

Note 10 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	10.	Subsequent Event
	Public Offering of Common Stock
	On February 20, 2015, the Company completed a public offering of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $8.0 million, which is net of $983,000 in underwriter commissions and estimated offering expenses. On February 26, 2015, the underwriters exercised their overallotment option for 482,142 additional shares of the Company’s common stock, for net cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions. In connection with this offering, as a portion of the underwriting compensation payable to the underwriters, the Company issued warrants to purchase 160,714 shares of its common stock to the representative of the underwriters. The warrants are exercisable at any time from February 2016 through February 2020 at an exercise price of $3.50 per share.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in the Company’s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial statements have been made for revenue, depreciation of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash
	The Company considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents. Cash is currently comprised only of cash on hand and deposits in banks. At December 31, 2014 and 2013, the Company had $50,000 in a restricted money market account that was held as cash collateral against an outstanding letter of credit for security on a lease.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts
	Accounts receivable are recorded net of an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience since its inception for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will not be recovered.
	During the year ended December 31, 2014, the Company discovered that $78,000 of insurance reimbursements were sent directly to patients, in error, and identified $99,000 of older Medicare and contracted insurance claims that were past the due date requirements. When the amounts were determined to be uncollectible, they were expensed as bad debt and subsequently charged off against the allowance.  Therefore, there were no allowances for doubtful accounts recorded as of December 31, 2014 or 2013.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory, which consists entirely of raw materials, and includes laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (“FIFO”) method.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
	Property and equipment is carried at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to ten years. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in operations.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long Lived Assets
	Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years ended December 31, 2014 or 2013.
Deferred Charges, Policy [Policy Text Block]	Deferred Offering Costs
	During the years ended December 31, 2014 and 2013, the Company incurred $47,000 and $655,000, respectively, in direct costs related to its anticipated public offerings of common stock. These costs were deferred and recorded as a long-term asset at December 31, 2014 and 2013 and reclassified as a reduction to additional paid-in capital upon completion of the respective offerings in 2015 and 2014, respectively.
Lease, Policy [Policy Text Block]	Deferred Rent
	Where rent abatements are made available to the Company under the terms of a lease agreement, the abatements are accounted for as a reduction of rent expense over the life of the lease and rent expense is recognized on a straight-line basis over the entire term of the lease. The cumulative difference between actual rent payments and recognized rental expense is recorded as deferred rent in the consolidated balance sheets.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	Revenues that are derived from testing services are recognized in accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
	Revenues are recorded on an accrual basis when the contractual obligations are completed as assays are processed through the Company’s laboratory and test results are delivered to ordering physicians. Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies and directly billed customers are reported based on the contractual rate. The contractual rate is based on established agreed upon rates between the Company and the respective payor. Directly billed customers are invoiced the contractual rate by the Company. Revenues from non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or payor group, as appropriate. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The difference between the amounts billed and the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized, to arrive at reported net revenue. The Company does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial to date.
	The Company’s estimates of net revenue for non-contracted insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience for non-contracted payors and adjusts expected revenues for current and subsequent periods accordingly. During the year ended December 31, 2014, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000 and $274,000 related to revenues previously recorded during 2012 and 2013, respectively. During the year ended December 31, 2013, net unfavorable changes in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $57,000.
	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
		Years Ended December 31,
	(in thousands)	2014			2013
	Gross revenues	$	6,484		$	5,491
	Less: contractual allowance		(2,164	)		(1,175	)
	Net revenue	$	4,320		$	4,316
	Contractual allowances recorded during the years ended December 31, 2014 and 2013 represented 33% and 21% of gross revenues, respectively. The increase in contractual allowances is primarily due to net unfavorable changes in estimates of $541,000 recorded during the year ended December 31, 2014 related to current and prior years’ revenue.
Cost of Sales, Policy [Policy Text Block]	Cost of Revenue
	Cost of revenue represents the cost of materials, personnel costs, costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary to render an individualized test result, depreciation, amortization and royalty expense. Costs associated with performing tests are recorded as the tests are processed.
License Fees Policy [Policy Text Block]	Royalties
	The Company licenses technology for patents for uses of a gene expression profiling (“GEP”) assay called MyPRS® and its related technology. Under the terms of the license agreement, the Company is required to pay royalties to UAMS. The royalties are calculated as a fixed percentage of the net revenue received from third parties that the Company generates from using this technology. The Company accrues for such royalties when incurred, which is based on when revenue is collected. Such royalties are included in cost of revenue in the accompanying consolidated statements of operations.
Research and Development Expense, Policy [Policy Text Block]	Research and Development
	Costs associated with research and development activities are expensed as incurred. Research and development costs primarily include personnel costs, laboratory supplies, reagents and consulting costs. To date, the Company has not included an allocation of any indirect costs in research and development.
Income Tax, Policy [Policy Text Block]	Income Taxes
	Prior to the Corporate Conversion, the Company was a limited liability company, which is not a tax paying entity at the corporate level. Each member was instead individually responsible for such member’s share of the Company’s income or loss for income tax reporting purposes. Net operating losses incurred by the Company through the date of the Corporate Conversion have been, or will be, used by the members to offset gains on other interests and are, therefore, not able to be carried forward to the Company.
	Effective as of the Corporate Conversion, deferred tax assets and liabilities are recorded for the expected future tax consequences of events that have been included in the consolidated financial statements or income tax returns. Deferred taxes are determined on the basis of the differences between the carrying amount of assets and liabilities for financial statement and income tax purposes at enacted rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.
	Applicable accounting guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. Accounting provisions also require that a change in judgment that results in subsequent recognition, derecognition, or change in a measurement of a tax position taken in a prior annual period (including any related interest and penalties) be recognized as a discrete item in the period in which the change occurs. The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and state filings by considering all relevant facts, circumstances, and information available.
	Any interest and penalties related to unrecognized tax benefits are classified as a component of income tax expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	Compensation expense for all stock-based payments made to employees, directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted using the Black-Scholes-Merton (“BSM”), option-pricing model, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees is estimated at the date of grant, while the fair value of stock options granted to non-employees is estimated at the date of grant using the BSM pricing model and remeasured at each subsequent reporting date to fair value until performance is complete, with changes in fair value recognized as expense in the statement of operations and comprehensive loss.
	The fair value of restricted stock units issued to employees is based on the market price of the Company’s common stock on the date of grant and, for nonemployees, at the date when performance is complete. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized as additional stock-based compensation expense.
	Stock-based compensation cost is recognized on a straight-line basis over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period in which the change in estimate occurs.
	Due to the Company’s net loss position, no tax benefits for stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash, restricted cash, accounts receivable, accounts payable, amounts due to related party and notes payable.
	The carrying amounts of financial instruments such as accounts receivable and accounts payable approximate their relative fair values due to the short-term maturities of these instruments.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
	Level 2—Includes other inputs that are directly or indirectly observable in the marketplace.
	Level 3—Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.
	At December 31, 2014 and 2013, the fair value of the Company’s remaining lease liability on its vacated facility was measured using estimated net cash flows, discounted using a nominal risk-free rate, which are considered Level 3 inputs. The present value of the remaining lease liability at December 31, 2014 and 2013 was $248,000 and $578,000, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share
	Basic and diluted net loss per common share for the periods presented is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted stock units from the date of vesting.
	For all periods presented, the number of shares outstanding has been adjusted to reflect the Corporate Conversion completed on June 17, 2014 as if it had occurred as of the beginning of the respective periods presented.
	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
		December 31,
		2014
	Unvested restricted stock units		655,200
	Options to purchase common stock		152,000
	Warrants to purchase common stock		42,500
	Total		849,700
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk, Major Customers and Suppliers
	Cash is maintained at two financial institutions and, at times, balances may exceed federally insured limits. The Company has not experienced any losses related to these balances.
	During the years ended December 31, 2014 and 2013, the Company had one major customer, UAMS. Revenue sourced either from or through UAMS accounted for 84% and 83% of net revenue during the years ended December 31, 2014 and 2013, respectively. Accounts receivable sourced either from or through UAMS at December 31, 2014 and 2013 accounted for 63% and 62% of total accounts receivable outstanding, respectively.
	Inventory used in the Company’s testing process is procured from one supplier. Any supply interruption or an increase in demand beyond such supplier’s capabilities could have an adverse impact on the Company’s business. Management believes it could identify alternative suppliers, if necessary, but it is possible such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company’s business.
Reclassification, Policy [Policy Text Block]	Reclassifications
	Reclassifications of certain current liabilities in the consolidated balance sheet and operating expenses in the consolidated statement of operations have been made as of and during the year ended December 31, 2013 to conform to the 2014 presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	In February 2015, the Financial Accounting Standards Board ("FASB") issued amendments to Accounting Standards Update (“ASU”) 2015-02, Consolidation: Amendments to the Consolidation Analysis. This standard simplifies consolidation accounting by reducing the number of consolidation models and changing various aspects of current GAAP, including certain consolidation criteria for variable interest entities. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In January 2015, the FASB issued ASU 2015-01, Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Under this standard, an entity will no longer be allowed to separately disclose extraordinary items, net of tax, in the income statement after income from continuing operations if an event or transaction is unusual in nature and occurs infrequently. This standard becomes effective for the Company’s first quarter beginning January 1, 2016 with early adoption permitted. Upon adoption, the Company may elect prospective or retrospective application. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance. This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized from costs incurred to fulfill a contract and becomes effective for the Company’s annual reporting period beginning January 1, 2017, including interim periods within that reporting period; early adoption is not permitted. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, which provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, this standard also outlines disclosures that are required in the company’s footnotes based on whether or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company’s annual reporting period beginning January 1, 2017, and for any annual and interim periods thereafter. Early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
	Future Accounting Pronouncements
	Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) provides that an emerging growth company, such as the Company, may take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Although, to date, the Company has not taken advantage of this delay, the Company has elected to avail itself of the extended transition period for adopting new or revised accounting standards in the future. As a result of this election, the Company’s consolidated financial statements may not be comparable to companies that comply with public company effective dates.

Note_2_Significant_Accounting_1

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Reconciliation Of Gross Revenues To Net Revenues [Table Text Block]	The table below shows the adjustments made to gross revenues to arrive at net revenues, the amount reported in the consolidated statements of operations:
		Years Ended December 31,
	(in thousands)	2014			2013
	Gross revenues	$	6,484		$	5,491
	Less: contractual allowance		(2,164	)		(1,175	)
	Net revenue	$	4,320		$	4,316
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Common stock equivalents that could potentially reduce net income per common share in the future that were not included in the determination of diluted loss per common share as their effects were antidilutive are as follows:
		December 31,
		2014
	Unvested restricted stock units		655,200
	Options to purchase common stock		152,000
	Warrants to purchase common stock		42,500
	Total		849,700

Note_3_Balance_Sheet_Accounts_1

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consist of the following:
		December 31,
	(in thousands)	2014			2013
	Laboratory and computer equipment	$	1,711		$	1,320
	Furniture and fixtures		52			13
	Leasehold improvements		6			6
			1,769			1,339
	Less: accumulated depreciation and amortization		(555	)		(411	)
	Total property and equipment, net	$	1,214		$	928
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following:
		December 31,
	(in thousands)	2014			2013
	Accrued compensation and related expenses	$	257		$	76
	Accrued offering costs		42			155
	Other		62			40
	Total accrued expenses	$	361		$	271

Note_5_Stockholders_EquityMemb1

Note 5 - Stockholders’ Equity/Members’ Interests (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Common Stock Shares Reserved For Future Issuance [Table Text Block]	Common shares reserved for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December 31, 2014 is as follows:
	Issued and Outstanding:
	Restricted stock units		940,093
	Stock options		152,000
	Warrants		42,500
	Shares reserved for future award grants		153,306
	Total		1,287,899
Schedule of Share-based Payment Award, Nonemployee, Valuation Assumptions [Table Text Block]	The estimated fair values of the warrants and stock option award were determined on their respective measurement dates using the BSM option valuation model with the following assumptions:
		Warrants			Options
	Fair value of common stock	$	7.84		$	10
	Exercise price	$	12.5		$	9.3
	Risk-free interest rate		1.72	%		0.035	%
	Volatility		64.6	%		63	%
	Dividend Yield		0	%		0	%
	Contractual term (in years)		5			0.12
	Weighted-average measurement date fair value per share	$	3.38		$	1.23

Note_6_Stock_Compensation_Plan1

Note 6 - Stock Compensation Plan (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	The following table summarizes activity related to RSUs during the year ended December 31, 2014:
			Number of			Weighted-
			Shares			Average Grant
						Date Fair Value
						per Share
	Granted during the year ended December 31, 2014			940,093		$	9.44
	Vested and unissued			(284,893	)	$	10
	Unvested at December 31,2014			655,200		$	9.2
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the activity related to stock option awards during the year ended December 31, 2014 is as follows:
			Shares Subject			Weighted-		Weighted-		Aggregate
			to Options			Average		Average		Intrinsic Value
						Exercise Price		Remaining		(in thousands)
						per Share		Contractual
								Term
								(in years)
	Granted			154,500		$	4.55
	Forfeitures and cancellations			(2,500	)	$	5.43
	Outstanding at December 31, 2014			152,000		$	4.53		3.7	$	—
	Options exercisable at December 31, 2014			—		$	—		—	$	—
	Options vested or expected to vest at December 31, 2014			152,000		$	4.53		3.7	$	—
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The estimated fair value of each stock option award was determined on the date of grant using the BSM option valuation model with the following assumptions for the option grants during the year ended December 31, 2014:
	Risk-free interest rate	1.73%	-	2.03%
	Expected volatility	65.30%	-	66.90%
	Weighted-average volatility		66.30%
	Dividend yield		0%
	Expected term (in years)		6.3
	Weighted-average grant date fair value per share		$2.81
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Total non-cash stock-based compensation expense for all stock awards that was recognized in the consolidated statements of operations during the year ended December 31, 2014 is as follows:
	(in thousands)
	Cost of revenue		$	257
	Research and development			121
	Selling and marketing			16
	General and administrative			3,904
	Total		$	4,298

Note_8_Income_Taxes_Tables

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The principal items accounting for the difference in income taxes computed at the federal statutory tax rate of 34% and the effective income tax rate for the Company’s operations subsequent to the Corporate Conversion in June 2014 through December 31, 2014 are as follows:
	(in thousands)
	Federal tax at statutory rate	$	(2,682	)
	Signal Genetics LLC loss, prior to Corporate Conversion, not taxed at corporate level		425
	State taxes, net of federal benefit		(141	)
	Change in valuation allowance		1,356
	Nondeductible compensation		1,046
	Credits and other		(4	)
	Total provision for income taxes	$	—
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2014 are as follows:
	(in thousands)
	Deferred Tax Assets:
	Net operating loss carryforwards	$	853
	Stock compensation		463
	Accrued compensation		74
	Credit carryforward		6
	Total deferred tax assets		1,396
	Valuation allowance		(1,196	)
	Deferred tax assets, net of valuation allowance		200
	Deferred tax liabilities:
	Depreciation and amortization		(200	)
	Net deferred tax assets	$	—

Note_9_Revision_of_Quarterly_L1

Note 9 - Revision of Quarterly Losses Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	The impact of the adjustments from the restatement is set forth below. The restatement had no effect on the consolidated balance sheets, stockholders’ equity or operating, investing or financing cash flows.
	(in thousands, except share and per share data)	For the Quarter Ended September 30, 2014									For the Nine Months Ended September 30, 2014
		As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	$	(1,637	)	$	—		$	(1,637	)	$	(5,632	)	$	—		$	(5,632	)
	Net loss per common share, basic and diluted	$	(0.43	)	$	0.03		$	(0.40	)	$	(1.78	)	$	(1.63	)	$	(3.41	)
	Weighted-average number of shares outstanding, basic and diluted		3,782,629			279,858			4,062,487			3,162,639			(1,509,992	)		1,652,647
		For the Quarter Ended June 30, 2014									For the Six Months Ended June 30, 2014
		As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	$	(3,289	)	$	—		$	(3,289	)	$	(3,995	)	$	—		$	(3,995	)
	Net loss per common share, basic and diluted	$	(1.13	)	$	(3.60	)	$	(4.73	)	$	(1.40	)	$	(7.52	)	$	(8.92	)
	Weighted-average number of shares outstanding, basic and diluted		2,903,040			(2,207,586	)		695,454			2,847,505			(2,399,778	)		447,727
	(in thousands, except share and per share data)	For the Quarter Ended September 30, 2013									For the Nine Months Ended September 30, 2013
		As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	$	(940	)	$	—		$	(940	)	$	(2,196	)	$	—		$	(2,196	)
	Net loss per common share, basic and diluted	$	(0.35	)	$	(4.35	)	$	(4.70	)	$	(0.85	)	$	(10.13	)	$	(10.98	)
	Weighted-average number of shares outstanding, basic and diluted		2,672,349			(2,472,349	)		200,000			2,587,475			(2,387,475	)		200,000
		For the Quarter Ended June 30, 2013									For the Six Months Ended June 30, 2013
		As Reported			Adjustments			As Restated			As Reported			Adjustments			As Restated
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	$	(630	)	$	—		$	(630	)	$	(1,257	)	$	—		$	(1,257	)
	Net loss per common share, basic and diluted	$	(0.24	)	$	(2.91	)	$	(3.15	)	$	(0.49	)	$	(5.80	)	$	(6.29	)
	Weighted-average number of shares outstanding, basic and diluted		2,591,223			(2,391,223	)		200,000			2,545,013			(2,345,013	)		200,000

Note_1_Basis_of_Presentation_D

Note 1 - Basis of Presentation (Details) (USD $)	0 Months Ended		12 Months Ended
	Jun. 23, 2014	Jun. 17, 2014	Dec. 31, 2014	Jun. 17, 2014
Note 1 - Basis of Presentation (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)		$27,300,000
Stock Issued During Period, Shares, Conversion of Units		2,932,629
Share Price (in Dollars per share)		$10		$10
Proceeds from Issuance Initial Public Offering (in Dollars)	6,100,000
Adjustments to Additional Paid in Capital, Other (in Dollars)			300,000
IPO [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	850,000
Share Price (in Dollars per share)	$10
Proceeds from Issuance Initial Public Offering (in Dollars)	6,100,000
Payments of Stock Issuance Costs (in Dollars)	2,400,000
Adjustments to Additional Paid in Capital, Other (in Dollars)	$5,800,000
Conversion of Class A Units [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Units		200,000
Conversion of Class C Units [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Units		2,732,629
Capital Unit, Class C [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		2,732,629
Stock Issued During Period, Shares, Conversion of Units		2,732,629
Minimum [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Liquidity In Cash, Term			12 months
Maximum [Member]
Note 1 - Basis of Presentation (Details) [Line Items]
Liquidity In Cash, Term			15 months

Note_2_Significant_Accounting_2

Note 2 - Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 2 - Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents, Current	$50,000	$50,000
Provision for Doubtful Accounts	177,000
Allowance for Doubtful Accounts Receivable	0	0
Impairment of Long-Lived Assets Held-for-use	0	0
Deferred Finance Costs, Noncurrent, Gross	47,000	655,000
Contractual Allowances Percentage	33.00%	21.00%
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options	0	0
Number Of Major Suppliers	1
Letter of Credit [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents, Current	50,000	50,000
UAMS [Member] | Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	84.00%	83.00%
UAMS [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	63.00%	62.00%
Recorded In 2012 [Member] | Sales Returns and Allowances [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Estimated Non-contracted Revenues, Adjustment	-106,000
Recorded In 2013 [Member] | Sales Returns and Allowances [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Estimated Non-contracted Revenues, Adjustment	-274,000
Fair Value, Inputs, Level 3 [Member] | Property Subject to Operating Lease [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Commitments, Fair Value Disclosure	248,000	578,000
Sales Returns and Allowances [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Estimated Non-contracted Revenues, Adjustment	-380,000	-57,000
Estimated Contracted Revenues, Adjustment	-541,000
Minimum [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Insurance Reimbursement Errors [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Provision for Doubtful Accounts	78,000
Older Medicare and Contracted Insurance Claims [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Provision for Doubtful Accounts	$99,000
Customer Concentration Risk [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Number Of Major Customers	1	1

Note_2_Significant_Accounting_3

Note 2 - Significant Accounting Policies (Details) - Adjustments Made to Gross Revenues to Arrive at Net Revenues (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Adjustments Made to Gross Revenues to Arrive at Net Revenues [Abstract]
Gross revenues	$6,484	$5,491
Less: contractual allowance	-2,164	-1,175
Net revenue	$4,320	$4,316

Note_2_Significant_Accounting_4

Note 2 - Significant Accounting Policies (Details) - Antidilutive Securities Excluded from Earnings Per Share	12 Months Ended
	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	849,700
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	655,200
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	152,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	42,500

Note_3_Balance_Sheet_Accounts_2

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) (Laboratory and Computer Equipment [Member], USD $)	Dec. 31, 2014
Laboratory and Computer Equipment [Member]
Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) [Line Items]
Capital Leased Assets, Gross	$300,000

Note_3_Balance_Sheet_Accounts_3

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) - Property and Equipment (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment	$1,769	$1,339
	1,769	1,339
Less: accumulated depreciation and amortization	-555	-411
Total property and equipment, net	1,214	928
Laboratory and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,711	1,320
	1,711	1,320
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	52	13
	52	13
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6	6
	$6	$6

Note_3_Balance_Sheet_Accounts_4

Note 3 - Balance Sheet Accounts and Supplemental Disclosures (Details) - Accrued Expenses (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]
Accrued compensation and related expenses	$257	$76
Accrued offering costs	42	155
Other	62	40
Total accrued expenses	$361	$271

Note_4_Notes_Payable_and_Capit1

Note 4 - Notes Payable and Capital Lease Obligations (Details) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended		6 Months Ended	10 Months Ended
	Jun. 17, 2014	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 16, 2014	Oct. 31, 2014	Mar. 06, 2015
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Proceeds from Related Party Debt			$795,000	$12,566,000
Debt Conversion, Original Debt, Amount	27,300,000
Repayments of Related Party Debt				10,461,000
Notes Payable, Fair Value Disclosure				42,000
Capital Lease Obligation, Term			2 years
Capital Lease Obligations, Monthly Rent		7,200	7,200
Payments to Acquire Equipment on Lease		136,000
Capital Lease Obligations		164,000	164,000
Capital Lease Obligation, Unamortized Discount		8,000	8,000
Capital Leases, Future Minimum Payments Due, Next Twelve Months		86,000	86,000
Capital Leases, Future Minimum Payments Due in Two Years		86,000	86,000
Majority Shareholder [Member] | Related Party Debt, Used to Support Operations [Member] | Secured Note Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Majority Shareholder [Member] | Related Party Debt, Used to Support Operations [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Proceeds from Related Party Debt			795,000
Majority Shareholder [Member] | Advance to Pay for Certain Offering Expenses [Member] | Unsecured Note Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Increase (Decrease) in Notes Payable, Related Parties	45,000
Majority Shareholder [Member] | Secured Note Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Short-term Debt, Average Outstanding Amount				24,500,000	27,400,000
Interest Expense, Related Party			1,100,000	1,900,000
Majority Shareholder [Member] | Unsecured Note Payable [Member] | Subsequent Event [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Notes Payable, Related Parties							1,100,000
Majority Shareholder [Member] | Unsecured Note Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Increase (Decrease) in Notes Payable, Related Parties	1,000,000
Majority Shareholder [Member] | Related Party Debt, Used to Support Operations [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Proceeds from Related Party Debt				2,100,000
Majority Shareholder [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Proceeds from Related Party Debt				10,500,000
Repayments of Related Party Debt				9,300,000
Interest Paid Related Party				1,200,000
Secured Note Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Conversion, Original Debt, Amount	27,300,000
Secured Debt [Member] | Capital Unit, Class C [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	2,732,629
Notes Payable [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Instrument, Face Amount				182,000
Debt Instrument, Term				36 months
Debt Instrument, Periodic Payment				$5,320
Debt Instrument, Interest Rate During Period				3.40%		3.40%
Capital Unit, Class C [Member]
Note 4 - Notes Payable and Capital Lease Obligations (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	2,732,629

Note_5_Stockholders_EquityMemb2

Note 5 - Stockholders’ Equity/Members’ Interests (Details) (USD $)	0 Months Ended		12 Months Ended
	Jun. 23, 2014	Jun. 17, 2014	Dec. 31, 2014	Dec. 31, 2013	Jun. 16, 2014
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Preferred Stock, Shares Authorized			5,000,000	5,000,000
Preferred Stock, Shares Issued			0	0
Preferred Stock, Shares Outstanding			0	0
Common Stock, Shares Authorized			50,000,000	50,000,000
Common Stock, Shares, Issued			3,782,629	0
Common Stock, Shares, Outstanding			3,782,629	0
Stock Issued During Period, Shares, Conversion of Units		2,932,629
Share Price (in Dollars per share)		$10
Proceeds from Issuance Initial Public Offering (in Dollars)	$6,100,000
Adjustments to Additional Paid in Capital, Other (in Dollars)			300,000
Class of Warrant or Right, Issued During Period	42,500
Issuance of Stock and Warrants for Services or Claims (in Dollars)	143,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			154,500
Payments of Capital Distribution (in Dollars)				285,000
IPO [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Share Price (in Dollars per share)	$10
Stock Issued During Period, Shares, New Issues	850,000
Proceeds from Issuance Initial Public Offering (in Dollars)	6,100,000
Payments of Stock Issuance Costs (in Dollars)	2,400,000
Adjustments to Additional Paid in Capital, Other (in Dollars)	5,800,000
Additional Paid-in Capital [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other (in Dollars)	5,800,000		300,000
Underwriter Options [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Share Price (in Dollars per share)			$10
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	45 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	127,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)	$157,000
Unvested [Member] | Capital Unit, Class B [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Limited Partners' Capital Account, Units Outstanding					23,328
Capital Unit, Class A [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Limited Partners' Capital Account, Units Issued					72,500
Limited Partners' Capital Account, Units Outstanding					72,500
Stock Issued During Period, Shares, Conversion of Units		200,000
Capital Unit, Class B [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Limited Partners' Capital Account, Units Issued					41,088
Limited Partners' Capital Account, Units Outstanding					41,088
Capital Unit, Class C [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		2,732,629
Stock Issued During Period, Shares, Conversion of Units		2,732,629

Note_5_Stockholders_EquityMemb3

Note 5 - Stockholders’ Equity/Members’ Interests (Details) - Common Shares Reserved for Future Issuance	Dec. 31, 2014
Issued and Outstanding:
Stock options	152,000
Shares reserved for future award grants	153,306
Total	1,287,899
Restricted Stock Units (RSUs) [Member]
Issued and Outstanding:
Restricted stock units	940,093
Employee Stock Option [Member]
Issued and Outstanding:
Stock options	152,000
StockWarrants [Member]
Issued and Outstanding:
Warrants	42,500

Note_5_Stockholders_EquityMemb4

Note 5 - Stockholders’ Equity/Members’ Interests (Details) - BSM Option Valuation Model Assumptions (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 17, 2014
Note 5 - Stockholders’ Equity/Members’ Interests (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of common stock		$10
Warrant [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of common stock	$7.84
Exercise price	$12.50
Risk-free interest rate	1.72%
Volatility	64.60%
Dividend Yield	0.00%
Contractual term (in years)	5 years
Weighted-average measurement date fair value per share	$3.38
Underwriter Options [Member]
Note 5 - Stockholders’ Equity/Members’ Interests (Details) - BSM Option Valuation Model Assumptions [Line Items]
Fair value of common stock	$10
Exercise price	$9.30
Risk-free interest rate	0.04%
Volatility	63.00%
Dividend Yield	0.00%
Contractual term (in years)	43 days
Weighted-average measurement date fair value per share	$1.23

Note_6_Stock_Compensation_Plan2

Note 6 - Stock Compensation Plan (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	153,306
Restricted Stock Units (RSUs) [Member] | Minimum [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Restricted Stock Units (RSUs) [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)	940,093
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value (in Dollars)	2,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	4,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 328 days
Employee Stock Option [Member] | The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 255 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	392,000
The Plan [Member]
Note 6 - Stock Compensation Plan (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)	1,245,399
Share-based Compensation Arrangement by Share-based Payment Award, Number of Awards Outstanding (in Shares)	1,092,093
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	153,306

Note_6_Stock_Compensation_Plan3

Note 6 - Stock Compensation Plan (Details) - Restricted Stock Units Activity (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Note 6 - Stock Compensation Plan (Details) - Restricted Stock Units Activity [Line Items]
Granted during the year ended December 31, 2014	940,093
Granted during the year ended December 31, 2014	$9.44
Vested and unissued	-284,893
Vested and unissued	$10
Unvested at December 31,2014	655,200
Unvested at December 31,2014	$9.20

Note_6_Stock_Compensation_Plan4

Note 6 - Stock Compensation Plan (Details) - Stock Options Activity (USD $)	12 Months Ended
	Dec. 31, 2014
Stock Options Activity [Abstract]
Granted	154,500
Granted	$4.55
Forfeitures and cancellations	-2,500
Forfeitures and cancellations	$5.43
Outstanding at December 31, 2014	152,000
Outstanding at December 31, 2014	$4.53
Outstanding at December 31, 2014	3 years 255 days
Options vested or expected to vest at December 31, 2014	152,000
Options vested or expected to vest at December 31, 2014	$4.53
Options vested or expected to vest at December 31, 2014	3 years 255 days

Note_6_Stock_Compensation_Plan5

Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Weighted-average volatility	66.30%
Dividend yield	0.00%
Expected term (in years)	6 years 109 days
Weighted-average grant date fair value per share (in Dollars per share)	2.81
Minimum [Member]
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Risk-free interest rate	1.73%
Expected volatility	65.30%
Maximum [Member]
Note 6 - Stock Compensation Plan (Details) - BSM Option Valuation Model Assumptions [Line Items]
Risk-free interest rate	2.03%
Expected volatility	66.90%

Note_6_Stock_Compensation_Plan6

Note 6 - Stock Compensation Plan (Details) - Stock-based Compensation Expense Allocation (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$4,298
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	257
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	121
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	16
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$3,904

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Details) (USD $)	1 Months Ended		12 Months Ended			1 Months Ended
	Jan. 31, 2014	Aug. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2015	Mar. 31, 2014
Note 7 - Commitments and Contingencies (Details) [Line Items]
Operating Leases, Rent Expense, Net			$149,000	$76,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months			216,000
Operating Leases, Future Minimum Payments, Due in Two Years			192,000
Operating Leases, Future Minimum Payments, Due in Three Years			148,000
Operating Leases Abandoned, Number					1
Lease Termination Abandonment Payable				578,000
Lease Termination Abandonment Payable Current			248,000	319,000
Royalty Guarantees, Commitments, Amount			30,000
Royalty Expense			30,000	30,000
Letters of Credit Outstanding, Amount			50,000
Restricted Cash and Cash Equivalents			50,000
Litigation Settlement, Amount		350,000
Proceeds from Legal Settlements	250,000
Percentage of Litigation Settlement Claim on Gross Sales			10.00%
Gain Contingency, Unrecorded Amount			100,000
Accounts and Other Receivables, Net, Current			100,000	250,000
Gain (Loss) Related to Litigation Settlement			100,000	250,000
General and Administrative Expense [Member] | Termination Agreement [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Changed in Estimate Additional Expense			46,000
Subsequent Event [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Proceeds from Legal Settlements						100,000
Termination Agreement [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Lease Termination Abandonment Payable							565,000
Lease Termination Abandonment Balance Payable Monthly Installments							31,400
Lease Termination Abandonment Payable Current			248,000
Service Agreement for Billing and Collections [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Monthly Purchase Obligation			10,000
Payments for Fees			142,000	143,000
Purchase Obligation, Due in Next Twelve Months			120,000
Purchase Obligation, Due in Second Year			20,000
Minimum [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Percentage of Annual Minimum Royalty Fees			2.00%
Maximum [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Percentage of Annual Minimum Royalty Fees			4.00%
Lease for Laboratory and Office Facility [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Monthly Rent Expense			6,400
Lease for Office Space for Corporate Headquaters [Member]
Note 7 - Commitments and Contingencies (Details) [Line Items]
Monthly Rent Expense			$14,000
Operating Leases, Rent Expense, Annual Increase, Percentage			3.00%
Lessee Leasing Arrangements, Operating Leases, Renewal Term			36 months

Note_8_Income_Taxes_Details

Note 8 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Note 8 - Income Taxes (Details) [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Deferred Tax Assets, Valuation Allowance	$1,196,000
Deferred Tax Assets, Tax Credit Carryforwards	6,000
Domestic Tax Authority [Member]
Note 8 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	2,300,000
State and Local Jurisdiction [Member]
Note 8 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$2,200,000

Note_8_Income_Taxes_Details_Ef

Note 8 - Income Taxes (Details) - Effective Income Tax Rate (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Note 8 - Income Taxes (Details) - Effective Income Tax Rate [Line Items]
Federal tax at statutory rate	($2,682)
State taxes, net of federal benefit	-141
Change in valuation allowance	1,356
Nondeductible compensation	1,046
Credits and other	-4
Total provision for income taxes	0
Predecessor [Member]
Note 8 - Income Taxes (Details) - Effective Income Tax Rate [Line Items]
Federal tax at statutory rate	$425

Note_8_Income_Taxes_Details_De

Note 8 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014
Deferred Tax Assets:
Net operating loss carryforwards	$853,000
Stock compensation	463,000
Accrued compensation	74,000
Credit carryforward	6,000
Total deferred tax assets	1,396,000
Valuation allowance	-1,196,000
Deferred tax assets, net of valuation allowance	200,000
Deferred tax liabilities:
Depreciation and amortization	-200,000
Net deferred tax assets	$0

Note_9_Revision_of_Quarterly_L2

Note 9 - Revision of Quarterly Losses Per Share (Details) - Impact of Adjustments from Restatement (USD $)	3 Months Ended				6 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2013
Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	($1,637)	($3,289)	($940)	($630)	($3,995)	($1,257)	($5,632)	($2,196)	($7,890)	($2,445)
Net loss per common share, basic and diluted	($0.40)	($4.73)	($4.70)	($3.15)	($8.92)	($6.29)	($3.41)	($10.98)	($3.50)	($12.23)
Weighted-average number of shares outstanding, basic and diluted	4,062,487	695,454	200,000	200,000	447,727	200,000	1,652,647	200,000	2,255,864	200,000
Scenario, Previously Reported [Member]
Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC	($1,637)	($3,289)	($940)	($630)	($3,995)	($1,257)	($5,632)	($2,196)
Net loss per common share, basic and diluted	($0.43)	($1.13)	($0.35)	($0.24)	($1.40)	($0.49)	($1.78)	($0.85)
Weighted-average number of shares outstanding, basic and diluted	3,782,629	2,903,040	2,672,349	2,591,223	2,847,505	2,545,013	3,162,639	2,587,475
Scenario, Adjustment [Member]
Net loss per common share, basic and diluted	$0.03	($3.60)	($4.35)	($2.91)	($7.52)	($5.80)	($1.63)	($10.13)
Weighted-average number of shares outstanding, basic and diluted	279,858	-2,207,586	-2,472,349	-2,391,223	-2,399,778	-2,345,013	-1,509,992	-2,387,475

Note_10_Subsequent_Events_Deta

Note 10 - Subsequent Events (Details) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
	Jun. 23, 2014	Dec. 31, 2014	Dec. 31, 2013	Feb. 26, 2015	Feb. 20, 2015	Jun. 17, 2014
Note 10 - Subsequent Events (Details) [Line Items]
Share Price (in Dollars per share)						$10
Proceeds from Issuance of Common Stock		$6,644,000	($500,000)
Class of Warrant or Right, Issued During Period (in Shares)	42,500
Underwriter Options [Member] | Subsequent Event [Member]
Note 10 - Subsequent Events (Details) [Line Items]
Payments of Stock Issuance Costs				95,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)				482,142
Proceeds from Stock Options Exercised				1,300,000
Underwriter Options [Member]
Note 10 - Subsequent Events (Details) [Line Items]
Share Price (in Dollars per share)		$10
Subsequent Event [Member]
Note 10 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)					3,214,285
Share Price (in Dollars per share)					$2.80
Proceeds from Issuance of Common Stock					8,000,000
Payments of Stock Issuance Costs					$983,000
Class of Warrant or Right, Issued During Period (in Shares)				160,714
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$3.50